Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
47,000
Eli Lilly and Co News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
stocks
The trillion-dollar club: Are these mega-sized stocks still buys?
The biggest stocks got bigger this year, breaking multi-trillion-dollar milestones.
markets
December 2025 US stock market outlook: Where we see investment opportunities
Heading into year-end, Santa Claus Rally or AI exhaustion?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,000.70 | 41.30 | 0.46% |
| CAC 40 | 8,103.62 | 47.76 | -0.59% |
| DAX 40 | 24,209.94 | 78.46 | -0.32% |
| Dow JONES (US) | 48,257.63 | 122.74 | 0.25% |
| FTSE 100 | 9,841.49 | 55.93 | -0.57% |
| HKSE | 25,801.77 | 111.24 | 0.43% |
| NASDAQ | 23,450.66 | 143.04 | 0.61% |
| Nikkei 225 | 50,402.39 | 895.18 | 1.81% |
| NZX 50 Index | 13,508.30 | 174.90 | 1.31% |
| S&P 500 | 6,868.03 | 33.53 | 0.49% |
| S&P/ASX 200 | 8,699.90 | 39.70 | 0.46% |
| SSE Composite Index | 3,917.36 | 26.92 | 0.69% |